| 共 43 篇文章 |
|
Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing pattern Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing pattern.2013Jul Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice.Clin Exp Rheumatol 2013 Jul-Aug;Clin Ther Clin Ther 2009 Apr; 阅35 转0 评0 公众公开 14-12-02 16:38 |
Mechanism of action, indications and adverse effects of: etanercept, infliximab and adalimumab | CME The first approved TNF alpha blocker was etanercept (Enbrel) in May 1998.Tumor necrosis factor-α (TNF-α) is a cytokine central to many aspects of the inflammatory response. Macrophages, mast cells, and activated TH cells (especially TH1 cells) secrete TNF-α. TNF-α stimulates macrophages to produce cytotoxic metabo... 阅370 转2 评0 公众公开 14-10-09 11:28 |
) is an integrin receptor antagonist indicated for the treatment of adult patients with moderately to severely active ulcerative colitis and Crohn''s Disease who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator, or had an ina... 阅44 转0 评0 公众公开 14-09-26 11:26 |
Women had the longest average time until a change in treatment with Humira (3,191 days), followed by Enbrel (2,659 days) and Remicade (1,743 days). In men, the longest average time until treatment change was for Enbrel (2,224 days), followed by Remicade (1,545 days) and Humira (958 days). 阅98 转0 评0 公众公开 14-09-23 09:28 |
About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. 阅34 转0 评0 公众公开 14-09-10 23:17 |
Research and Markets: Brand Leaders in Rheumatoid Arthritis to Lose Market Share, Predict Rheumatolo Research and Markets: Brand Leaders in Rheumatoid Arthritis to Lose Market Share, Predict Rheumatolo.Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.Research and Markets is the world''s leading source for internat... 阅23 转0 评0 公众公开 14-09-10 23:16 |
The Rheumatoid Arthritis Drug Market Will Experience Modest Growth as Sales Increase from $11.1 Bill The Rheumatoid Arthritis Drug Market Will Experience Modest Growth as Sales Increase from $11.1 Bill.To be considered for the same line of therapy as the TNF-alpha inhibitors, new rheumatoid arthritis agents must show compelling advantages on price, be at least as effective as the TNF-alpha inhibitors and have no majo... 阅24 转0 评0 公众公开 14-09-10 23:04 |
进入本世纪以来，逐渐认识到各种炎性细胞及炎性细胞分泌的细胞因子在RA发病机制中的重要作用，越来越多针对各种炎性细胞和细胞因子的生物制剂也走到前台，从而宣告RA“生物治疗”时代的到来[1]。抑制这些细胞因子通常的方法包括：可溶性细胞因子受体;细胞因子受体拮抗剂;抗细胞因子单克隆抗体;人类Fc结构与细胞因子或可溶性细胞因子受体的融合... 阅1840 转9 评0 公众公开 14-07-25 09:36 |
TNF inhibitor therapy for rheumatoid arthritis (Review)Contents.Smolen JS, Han C, Bala M, et al ATTRACTStudy Group: Evidence of radiographic benefit of treatment withinfliximab plus methotrexate in rheumatoid arthritis patients whohad no clinical improvement: a detailed subanalysis of data fromthe anti-tumor necrosis ... 阅56 转0 评0 公众公开 14-07-24 17:01 |
共刺激分子受体CTLA.近几年来，在免疫应答中起重要调节作用的细胞毒T淋巴细胞抗原-4（CTLA-4）和CTLA-4免疫球蛋白（CTLA-4Ig）成为风湿病治疗中的热点。有研究显示CTLA-4（AT）n部位为较长等位基因个体的T细胞反应性增强，CTLA-4mRNA的稳定性降低，降解快速，CTLA-4蛋白表达水平下降，T细胞功能增强，最终导致T细胞活化阈值降低，使这些个体发... 阅1497 转8 评0 公众公开 14-07-24 10:32 |
